Physician profile
Latisha C Murray
NPI 1134481708
$2,354.16
in general payments reported to CMS, 2019-2025
22 companies · $734 in 2025
The $734 reported for 2025 was more than what 80% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $475 · 2023: $517 · 2024: $628 · 2025: $734.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,879.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,879.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $414.37 | 2022-2025 | Farxiga, Airsupra |
| Novo Nordisk INC | $341.12 | 2022-2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $301.18 | 2022-2025 | |
| Lilly USA, LLC | $222.70 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $209.09 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $163.52 | 2022-2025 | Jardiance, Synjardy |
| Otsuka America Pharmaceutical, INC. | $118.43 | 2022-2024 | Rexulti |
| Amgen INC. | $91.84 | 2022-2025 | Repatha, Otezla, Repatha |
| Biohaven Pharmaceutical Holding Company LTD. | $78.78 | 2022 | |
| Exact Sciences Corporation | $72.36 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Corium, LLC | $64.96 | 2022-2023 | Azstarys |
| Glaxosmithkline, LLC. | $62.27 | 2023-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Bioventus LLC | $35.88 | 2022 | |
| Boston Scientific Corporation | $33.99 | 2025 | Watchman Access System |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $23.56 | 2025 | Caplyta |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $20.76 | 2023 | Camzyos |
| Bausch Health US, LLC | $18.51 | 2022 | |
| Currax Pharmaceuticals LLC | $16.81 | 2022 | |
| Insulet Corporation | $16.75 | 2023 | Omnipod |
| Azurity Pharmaceuticals, INC. | $16.15 | 2025 | Azmiro |
| Merck Sharp & Dohme LLC | $15.59 | 2025 | Gardasil 9, Capvaxive |
| Axsome Therapeutics, INC. | $15.54 | 2023 | Sunosi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Latisha Murray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.